Department of Health and Human Services April 12, 2011 – Federal Register Recent Federal Regulation Documents
Results 1 - 18 of 18
Notice of Intent To Award Affordable Care Act (ACA) Funding
This notice provides public announcement of CDC's intent to award Affordable Care Act (ACA) appropriations to the Connecticut Department of Public Health and the Georgia Department of Community Health to conduct vaccine effectiveness activities for rotavirus vaccine and 13-valent pneumococcal conjugate vaccine (PCV). These activities were requested by the two grantees in their FY 2011 non- competitive continuation applications submitted under funding opportunity CI05-026, ``Emerging Infections Program (EIP),'' Catalogue of Federal Domestic Assistance Number (CFDA): 93.283. Due to a lack of funding availability, these activities were either approved but unfunded or only partially funded in the grantee's FY 2011 continuation award. Only these two EIP sites requested funding for the rotavirus activities and only one site (Georgia) requested funding for the PCV activities. Since no other EIP sites requested funding for these specific activities, Connecticut and Georgia will be the only sites receiving funding for these activities. Approximately $433,500 in ACA funding will be awarded, which includes $333,500 for Rotavirus and $100,000 for PCV, to increase the amount of funding available to evaluate the effectiveness of new rotavirus and PCV vaccines currently being monitored through the aforementioned participating EIP sites. Funding is appropriated under the Affordable Care Act (PL 111-148), Title IV, Section 4002 (Prevention and Public Health Fund). Accordingly, CDC adds the following information to the previously published funding opportunity announcement:
Notice of Intent To Award Supplemental Affordable Care Act Funding
This notice provides public announcement of CDC's intent to use Affordable Care Act (ACA) appropriations to expand the Emerging Infectious Diseases (EID) Laboratory Fellowship Program currently supported through Funding Opportunity CDC-RFA-HM10-1001, ``APHL-CDC Partnership for Quality Laboratory Practice.'' Funding is appropriated under the Affordable Care Act (Pub. L. 111-148), Title IV, Section 4002 (Prevention and Public Health Fund). In addition, Under Section 5314, Fellowship Training in Public Health (Part E of title VII of the Public Health Service Act (42 U.S.C. 294n et seq., as amended by section 5206, is further amended by Sec. 778), CDC is authorized to expand existing fellowship training programs in the critical areas of applied public health epidemiology, public health laboratory science and public health informatics. The CFDA Number for this funding opportunity is 93.065. CDC will add the following ACA Authority to that which is reflected in the published Funding Opportunity CDC-RFA-HM10-1001:
Determination That KEFLEX (Cephalexin) Capsule, Equivalent to 333 Milligrams Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA) has determined that KEFLEX (cephalexin) capsule, equivalent to (EQ) 333 milligrams (mg) base, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for cephalexin capsule, EQ 333 mg base, if all other legal and regulatory requirements are met.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
